Pharmaceutical Giant Picks Up Inhalable Insulin Tab

2053

On September 6, Generex Biotechnology of Toronto announced that Eli Lilly had agreed to market its oral insulin spray for diabetes in exchange for paying for the last stages of clinical trials and securing regulatory approvals.

Generex will receive initial fees and milestone payments from Eli Lilly, and eventual royalty payments when the insulin delivery system is approved for marketing.

Generex has spent approximately $25 million to develop the insulin-delivery system. It anticipates spending an additional $40 million to bring it to market.

Comments

comments

This post authored by
Diabetes Health Medical Disclaimer
The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. All content, including text, graphics, images, and information, contained on or available through this website is for general information purposes only. Opinions expressed here are the opinions of writers, contributors, and commentators, and are not necessarily those of Diabetes Health. Never disregard professional medical advice or delay seeking medical treatment because of something you have read on or accessed through this website.